Drug intelligence / Profile preview

HYNR-CS

Development stage: Unknown
Lead developer: Corestemchemon
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

HYNR-CS is an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy developed by Hyun Young Kim at Hanyang University for the treatment of anoxic or hypoxic brain injury. The treatment involves the isolation and expansion of a patient's own bone marrow MSCs, which are then administered via intrathecal injection. The therapeutic rationale is based on the cells' ability to exert neuroprotective effects through the paracrine secretion of various neurotrophic factors and immunomodulatory cytokines. These factors are intended to reduce neuroinflammation, prevent further neuronal apoptosis, and potentially stimulate endogenous neural repair mechanisms in brain tissue damaged by a lack of oxygen.

Other names: Autologous bone marrow-derived mesenchymal stem cellsHYNR-CS injection

Beyond the preview

Go deeper on HYNR-CS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HYNR-CS.

Explore the full profile